Post-Traumatic Stress Disorder (PTSD)

Post-traumatic stress disorder is an increasingly studied HBOT target. A sham-controlled randomised trial in combat veterans reported substantial reductions in PTSD severity alongside measurable changes in brain connectivity, with early independent corroboration. The randomised evidence comes largely from one research group; HBOT for PTSD remains investigational and is not FDA-approved.